Last reviewed 2026-04-20 · How we verify

Nevirapine and Efavirenz

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Nasopharyngitis
• Upper respiratory tract infection
• Diarrhoea
• Headache
• Arthralgia
• Cough
• Back pain
• Pain in extremity
• Bronchitis
• Fatigue
• Nausea
• Syphilis

Key clinical trials

• Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
• A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
• Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
• Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
• Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
• Research on the Psychological Status of Patients With HIV-1 Infection
• Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen (PHASE2, PHASE3)
• A Prospective Cohort of Children With HIV Infection

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Nevirapine and Efavirenz CI brief — competitive landscape report
• Nevirapine and Efavirenz updates RSS · CI watch RSS
• Vanderbilt University portfolio CI